Correction by 
Parental Exposure to Dioxin
and Offspring Sex Ratios
I would like to respond to the comments of
Jongbloet et al. (1) on the data of Mocarelli
et al. (2). Mocarelli et al. (2) reported on
the offspring sex ratios (proportions male)
following the explosion at Seveso, Italy,
that released 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD, dioxin) into the environ-
ment. Mocarelli et al. (2) categorized
matings into the four possible combina-
tions by sex and exposed versus unexposed.
Their analysis yielded one unequivocal
result and one equivocal one: a) exposed
men mated to unexposed women produced
offspring with a a significantly low sex
ratio; and b) exposed women mated to
unexposed men produced offspring with a
nonsignificantly high sex ratio.
Jongbloet et al. (1) explained both of
these phenomena by their hypothesis of
preovulatory and postovulatory over-
ripeness, and they claimed that it is more
plausible than my hormonal hypothesis (3).
Because I had predicted that exposed men
would sire an excess of daughters (3), my
hypothesis—at least initially—seemed
preferable. However, it now seems that these
theories (both theirs and mine) may be pre-
mature: paternal exposure to organochlorine
compounds has been reported to be fol-
lowed by significant excesses of daughters
(2,4), a nonsignificant excess of sons (5), and
a significant excess of sons (6). This disarray
may be potentially explained in several ways: 
• The various organochlorine compounds
may actually have different effects on the
offspring sex ratio of exposed men. This
may not be accurate because opposite
effects have been reported in respect of
dioxin itself. 
• The organochlorine compounds may have
opposite effects on exposed mothers and
exposed fathers, thus suggesting the possi-
bility of confounding. However, both
Mocarelli et al. (2) and Karmaus et al. (6)
assessed paternal and maternal exposures
and yet reached opposite conclusions
(admittedly in one case on TCDD and in
the other on polychlorinated biphenyls).
• It is possible that the different exposures
may have been to different congeners
and/or contaminants and that these conta-
minants had causal effects. 
Logically, Jongbloet’s hypothesis and
mine are not mutually exclusive: both may
be applicable, either separately or simultane-
ously. I subscribe to the appeal of Jongbloet
et al. (1) for more research on the effects of
organochlorine compounds on mammalian
offspring sex ratios, and I welcome their
predictions.
William H. James
The Galton Laboratory
University College London
London, England
Fax: 44-207-383-2048 
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Dioxin and Offspring Sex
Ratios: Jongbloet et al.’s
Response
We are very pleased with James’ comments
on the sex ratio shifts after the dioxin disas-
ter in Seveso (1) and his appreciation of our
explanation of these phenomena. He men-
tions the disarray of results after exposure to
organochlorine compounds and concludes
that our and his own hormonal hypothesis
“are not mutually exclusive” and that “both
may be applicable, either separately or
simultaneously.” We like to stress, however,
the added value and the parsimony of the
overripeness ovopathy concept.
We agree that both hypotheses are con-
cerned with the hormonal concentrations
around the time of conception and that the
antiestrogenic effects of the organochlorine
compounds affect both paternal and mater-
nal reproductive pathways. The increase of
male-biased fetuses and subsequently (after
having reached a critical threshold) the
decrease due to loss of them, however, can
only be understood by a dose–response fal-
lacy. Nonoptimally matured oocytes—pref-
erentially inseminated by Y-bearing
spermatocytes and preferential loss of male
fetuses—are supposed to be the key for elu-
cidating this dose–response fallacy in mam-
mals, including humans (1,2).This explains
a) the mentioned disarray of varying and
controversial results (either more sons or
more daughters); b) the difficulties in reach-
ing statistically significant results; c) the
analogy with other high-risk conception
categories in which the maturation of the
oocyte is at stake (e.g., in very young and
premenopausal mothers, in very short or
unintendedly long interpregnancy intervals,
in transitional stages between ovulatory and
anovulatory seasons, etc.) (1,2); and d) the
reduced quality of cumulus expansion,
impaired maturation, fertilization, and
embryonic development of porcine oocytes
(3), besides the wide spectrum of reproduc-
tive disorders from menstrual disturbances,
subfecundity, spontaneous abortions, still-
births, and congenital malformations up to
neurologic deficits in human progeny (4).
This cluster of phenomena is not explained
either by the prevailing theories or by
James’ hormonal hypothesis. 
Piet Hein Jongbloet
Nel Roeleveld
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Mechanistic and Epidemiologic
Data: When Is Enough Enough?
In the current draft of the U.S.
Environmental Protection Agency’s (EPA)
Guidelines for Cancer Risk Assessment (1),
animal carcinogens are considered “likely to
be carcinogenic to humans” if the weight of
experimental evidence indicates a mode of
action (MOA) that can be assumed to be, or
is known to be, relevant to humans. The
wording of this guideline begs the question,
“Who is assessing the relevance for humans
of the experimental MOA?” Similarly, the
category of “not likely to be carcinogenic to
humans” requires “extensive experimental
evidence showing that the only carcinogenic
effects observed in animals are not consid-
ered relevant to humans” (1). The criteria for
judging data places emphasis on “the degree
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scientists” (1). However, experience demon-
strates that such consensus is rare, primarily
due to the healthy tendency of scientists to
present constructive challenge to the reason-
ing of their peers. Even when an MOA is
accepted by a majority, some will still call for
more data. For example, Melnick of the
National Institute of Environmental Health
Sciences appears to accept, albeit tentatively,
the proposed MOA for the rodent hepatocar-
cinogenicity of the peroxisome proliferators,
but he also suggested that this knowledge is
inadequate to judge human relevance (2).
Thus, as long as some investigators assume
that the rodent cancer data for a chemical are
relevant to humans, implementation of the
guidelines would require a subjective decision
by the agency. This issue is also illustrated by
the near, but imperfect, “consensus” on the
α2µ-globulin mechanism of male rat renal
carcinogenesis induced by d-limonene and its
lack of relevance for humans. The extent of
the data set addressing rodent MOA and
human relevance underpins the view of
many, including the International Agency
for Research on Cancer (IARC), that the
MOA for d-limonene is “through an α2µ-
globulin associated response which is not rel-
evant to humans” (3–5). Nonetheless, in this
context, some still call for the unobtainable
goal of “incontrovertible proof [in] … our
rightful quest to identify mechanisms of
chemical carcinogenesis” (6). The question is
“When does negative data constitute incon-
trovertible proof?” 
Similar issues are raised by the U.S. EPA
requirement for “extensive human epidemi-
ology that demonstrates lack of carcinogenic
effect” when considering the category “not
likely to be carcinogenic to humans” (1).
Practical implementation of this guideline
would require the registrant to prove a nega-
tive result with respect to epidemiology data.
It may be that such language is intended to
allow the U.S. EPA freedom of interpreta-
tion, but this language seems to imply rigid-
ity rather than adaptability. This is in
contrast to the implementation of the
Bradford Hill criteria, cited by the U.S. EPA
(1), which were devised to assess the strength
of an association between exposure and can-
cer in humans, not to prove a negative result.
When no association is found in relevant,
adequately powered, and well-conducted epi-
demiologic studies, the only valid conclusion
is that there is no effect. A lack of definition
of the required nature and power of epidemi-
ology studies opens the door to individuals
who will always call for more data before the
issue can be resolved. An example of this is
the hypolipidemic drug and rodent hepa-
tocarcinogen clofibrate. IARC (7) concluded
that “the mechanism of liver carcinogenesis
in clofibrate treated rats would not be opera-
tive in humans.” This was based on the
observation that clofibrate causes peroxisome
proliferation and cell proliferation in rodent
but not human hepatocytes and on the
results of extensive epidemiologic studies (7),
particularly the World Health Organization
trial on clofibrate including 208,000 man-
years of observation (8,9). Further, in a meta-
analysis of the results from six clinical trials
on clofibrate, Law et al. (10) found no excess
cancer mortality. Despite this weight of evi-
dence, Melnick (2) has suggested that these
epidemiologic data are “insufficient to permit
a definite conclusion on the presence or
absence of a causal association between expo-
sure to lipid lowering drugs and cancer.” The
lack of definition of the required nature and
power of epidemiology studies would require
individuals in the U.S. EPA to either set their
own standards or to use default procedures in
order to implement the guideline. This is in
marked contrast to IARC, where clear guid-
ance is given concerning the types of epi-
demiology studies that can be considered, the
required quality of those studies, and the cri-
teria for causality. Without refinement, there
remains the possibility that the U.S. EPA
might dismiss from the hazard assessment
process epidemiologic data that fail to iden-
tify an association between chemical exposure
and cancer, even when these studies show
sufficient power to detect a cancer increase. A
more meaningful use of such data would be
to conclude that there is no evidence of car-
cinogenicity in humans based on epidemiol-
ogy studies with a given resolving power. 
To provide impetus to continuing
mechanistic and epidemiologic studies, reg-
ulatory agencies need to give precise guid-
ance on the extent of data required to
influence the categorization of a chemical. 
Ruth Roberts
John Ashby
Syngenta CTL
Alderley Park, United Kingdom
E-mail: ruth.roberts@syngenta.com
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Duration of Breast-Feeding
and PBBs
Thomas et al. (1) report that polybrominated
biphenyl (PBB) exposure has no effect on
duration of lactation. Their data come from
interviews in 1997 or later with women who
were exposed to PBBs in the mid-1970s and
who had a child since then. In a study con-
temporary with the exposure, however, Weil
(2) found that unexposed women breast-fed
about twice as long as exposed women (30
weeks vs. 15 weeks). This might have been
because of the warnings about breast-feeding
with PBB-contaminated milk (3), which we
recall as being more ominous than reported
by Thomas (1), or because of some biological
effect of PBB. In any event, the presence of
the finding then and its absence now causes
us to speculate that there may be poor recall
or other reasons why duration of lactation
does not work well as a recalled outcome.
Consistent with that speculation, cigarette
smoking by the mother (4) and infant’s ges-
tional age < 37 weeks (5), for example, are
usually associated with early weaning, but the
hazard ratios for these characteristics in the
report by Thomas et al. (1) are small and
nonsignificant. It is disappointing to think
that PBB did interfere with lactation but that
the effect cannot be detected in data about
lacation recalled years later. 
Walter J. Rogan
National Institute of Environmental
Health Sciences
Research Triangle Park, North Carolina
E-mail: rogan@niehs.nih.gov  
William B. Weil
Michigan State University
East Lansing, Michigan
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Breast-Feeding and PBBs:
Response to Rogan and Weil
We thank Rogan and Weil for their com-
ments. In our analyses we examined breast-
feeding among infants born between 1973
and 1998. We did not find an association
between PBB exposure and a decision to
breast-feed or breast-feeding duration.
Because the proportion of women who chose
to breast-feed their infants increased during
this 25-year period, we adjusted for year of
birth in 5-year intervals. This notation was
inadvertently left out of the footnote accom-
panying Table 6 of our paper (1). An interac-
tion term between year of birth and PBB
exposure did not contribute to any of the
multivariate models of breast-feeding.
Prompted by the comments of Rogan
and Weil we have now examined the possi-
bility of an interaction between birth cohort,
PBB exposure, and breast-feeding more
closely. Table 1 shows the proportion of
women who chose to breast-feed by PBB
exposure stratified by 5-year birth cohorts.
During the first 5 years after exposure
(1973–1978) we found a suggestion that
women with higher PBB exposure were less
likely to breast-feed their infants than
women with lower exposure, consistent with
the findings of Weil et al. (2). However, the
number of infants in this stratum was small
and the trend was not statistically significant
(p = 0.35). Multivariate analyses (adjusting
for maternal education and prior history of
breast-feeding) yielded similar, nonsignifi-
cant differences in breast-feeding by PBB
exposure for births from 1973 to 1978.
Among the women who chose to breast-
feed, there were no suggested differences in
duration of breast-feeding by PBB exposure
for any of the 5-year birth cohorts.
In summary, we found some suggestion
of an association between PBB exposure and
breast-feeding during the years immediately
after the PBB incident; however, the
association was weak and nonsignificant in
contrast to the strong association found by
Weil et al. (2). Weil et al. (2) found that 42%
of PBB exposed women breast-fed their
infants compared to 85% of control women.
In their letter, Rogan and Weil suggest that
inaccurate recall of breast-feeding may have
led us to underestimate the difference in
breast-feeding between the PBB-exposed
women and unexposed women. This is a
valid concern. Recall of breast-feeding behav-
ior is likely to decrease in accuracy as the
recall interval lengthens. However, we believe
that differences in recall play a small role in
the differences between our conclusions and
those of Weil et al. (2). In fact, our data (1)
and the data of Weil et al. (2) for breast-feed-
ing among PBB-exposed women are remark-
ably similar. We found that 47% of women
(27/57) enrolled in the PBB cohort (lived on
quarantined farms or obtained food from
quarantined farms) reported breast-feeding
their infants born between 1973 and 1978.
Weil et al. (2) found that 42% of women
(14/33) who lived on quarantined farms
reported breast-feeding their infants born
between 1973 and 1975. These figures are
also consistent with national data collected
during the same period. The National Survey
of Family Growth (3) found that 30% of
women in the United States breast-fed their
infants born between 1972 and 1974. That
proportion increased to 48% by 1978–1980
(3). The Ross Laboratories Mother Survey
(4) found breast-feeding rates of 29% in
1973 and 47% in 1978.
The major difference between Weil et al.’s
study (2) and our own (1) is the choice of
comparison group. Weil et al. (2) compared
the PBB-exposed women to a control group
of women obtained from two sources:
“… families in which the mother’s milk had
been tested for PBB and had been found neg-
ative …” and “… families who were identi-
fied by the school system as having moved to
Michigan since 1975.” Eighty-five percent of
women in this comparison group breast-fed
their infants, more than double the propor-
tion among PBB-exposed women in
Michigan and more than double the propor-
tion among U.S. women interviewed for the
National Survey of Family Growth (3). It is
possible that women who had a breast milk
sample tested for PBBs had already decided to
breast-feed their infants. In our study (1) we
compared breast-feeding among women in
the PBB cohort categorized by their estimated
serum PBB at the time of the pregnancy.
We acknowledge the assistance of the
Michigan Department of Community
Health. This research would not be possible
without their diligent maintenance of the
PBB Cohort Registry. 
Michele Marcus
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Paige E. Tolbert
Vicki Hertzberg
Chanley Small
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Atlanta, Georgia
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Chevron v. Echazabal: A
Sobering Decision for
Environmental Health Research
A recent Supreme Court decision (Chevron v.
Echazabal) may have important implications
for environmental health research (1). Risk-
factor research has made important contribu-
tions to workplace health and safety.
Systematic evaluation of the impact of chem-
ical and physical agents on disease occurrence
has provided information for the develop-
ment of policies for controlling injury and
disease. Research has focused predominantly
on the impact of external risk factors on
workers. With the advancement of molecular
genetic methods, researchers have begun to
identify individual risk factors believed to
affect the occurrence of disease. Considerable
attention has been given to identifying bio-
logical markers—markers of susceptibility,
exposure, or effect—that enable better
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Table 1. Number and percent of infants breast-fed by year of birth and PBB exposure status of mother in the
Michigan Female Health Study.
PBB exposure
Year of birth No. Low (≤ 1 ppb) Medium (1–7 ppb) High (> 7 ppb)
July 1973–June 1978 57 11/20 (55) 13/29 (45) 3/8 (38)
July 1978–June 1983 137 42/63 (67) 38/59 (64) 10/15 (67)
July 1983–June 1988 114 48/69 (70) 25/38 (66) 6/7 (86)
July 1988–June 1993 96 50/72 (69) 7/13 (54) 6/11 (55)
July 1993–June 1998 42 26/34 (76) 4/4 (100) 4/4 (100)characterization of disease risk resulting from
exposure. Studies investigating gene–environ-
ment interactions have identified DNA
markers (e.g., polymorphisms in metabolic
enzymes and allelic variation associated with
hypersensitivity) associated with elevated risk
for occupational disease.
In Chevron v. Echazabal, the court
addressed issues central to the Americans
with Disabilities Act (ADA). The ADA is
cited by some commentators as offering indi-
viduals protection from genetic discrimina-
tion (2,3). Others have questioned whether
regulations promulgated under the ADA by
the Equal Employment Opportunity
Commission offer such protection (4,5). The
recent decision addresses the case of a refinery
worker who was denied employment due to
chronic liver disease, which was eventually
identified as hepatitis C. Chevron sought to
exclude the individual based on the rationale
that his liver function was impaired and
would be subject to further damage if he
experienced chemical exposures characteristic
of refinery work. Conceptually, a preplace-
ment examination using a liver function assay
resulted in the identification of a biological
marker that the employer interpreted to sug-
gest a heightened susceptibility to disability
from workplace exposure.
At the heart of this ruling is the court’s
interpretation of the direct threat provision of
the ADA. A direct threat is defined as a sig-
nificant risk of substantial harm that cannot
be eliminated by reasonable accommodation
(6). An individual may be refused employ-
ment if a direct threat can be established.
Historically, there has been ambiguity over
the scope of the direct threat defense (5). In a
previous ruling [Echazabal v. Chevron (7)],
the Ninth Circuit Court held that the direct
threat defense was not available to Chevron
because Echazabal only presented a risk to
himself. The court reasoned that a direct
threat only applies when the individual’s con-
dition poses a direct threat to others. In other
words, the circuit court affirmed the notion
of health as a discretionary right in which the
individual may chose to assume certain risks
so long at they do not have the potential to
harm others. The recent Supreme Court
decision rejects this reasoning and reverses
the circuit court’s judgment. Individuals who
pose a risk exclusively to themselves may be
excluded from a job as long the employer
relies on reasonable medical judgment and
accounts for the duration of the risk and the
nature, severity, likelihood, and imminence
of the potential harm (6). 
In this example, Chevron produced evi-
dence identifying a severe disease in a
prospective employee and concluded that
Echazabal’s liver function was subject to fur-
ther damage under job conditions in the
refinery. Conceptually, Chevron based its
position, and the court concurred unani-
mously, on the identification of biological
evidence of clinical disease. Basing work-
place exclusion on evidence of clinical dis-
ease is substantively different from the
identification of DNA markers associated
with elevated risk for occupational illness,
and perhaps the court would recognize such
a difference and rule differently in the later
example. However, the difference between a
DNA marker of disease and susceptibility is
not always clear. It is conceivable that if the
DNA marker was sufficiently predictive of
an individual’s risk of a severe disease, then
the basis for a direct threat exclusion may
exist (8). Although this scenario is specula-
tive, the Supreme Court has unanimously
stated that a direct threat to self may serve as
the basis for workplace exclusion. 
This is a sobering decision for researchers
involved in risk factor research, some of
whom have articulated the belief that
assumption of risk is a discretionary right of
workers. Researchers and institutional
review boards should be mindful of this
decision when considering future research
into individual risk factors, particularly for
occupational disease.
Geoffrey Lomax 
University of California-Berkeley 
School of Public Health
Center for Occupational and
Environmental Health
Berkeley, California
E-mail: glomax@uclink4.berkeley.edu
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Corrections
In Figure 1 of the paper by Larsson et al.
[EHP 110:739–742 (2002)], the embryonic
sex ratios of eelpout broods (mean ± SEM)
for year 2000 were incorrect. The corrected
figure appears below. Values for 1997–1999
were correct.
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Table 2. Multiple linear regression analysis for log transformed protein HC (mg/mmol creatinine) as a function
of age, blood-cadmium, blood-lead, and smoking. 
Mena (n = 460) Womenb (n = 521)
Characteristics Regression coefficient 95% CI Regression coefficient 95% CI
Age (years) 0.023 0.019–0.028 0.017 0.013–0.020
Blood Cd (nmol/L) 0.016 0.0099–0.023 0.015 0.0049–0.025
Blood Pb (µmol/L) 0.015 –0.80–0.83 –0.19 –0.99–0.60
Smoking (never or former/current) –0.042 –0.18–0.096 0.028 –0.090–0.15
R2 = 0.26. bR2 = 0.17.
In “Cadmium and Lead in Blood in Relation to Low Bone Mineral Density and Tubular
Proteinuria” by Alfvén et al. [EHP 110:699–702 (2002)], the values for smoking in Table 2
and several of the 95% confidence intervals in Table 3 were incorrect. The corrected tables
appear below. EHP regrets the errors. 
Table 3. Multiple linear regression analysis of BMD for the subgroup ages 60 years and older, as a function of
age, weight, blood cadmium, blood lead, and smoking.
Men (n = 172)a Women (n = 176)b
Characteristics Regression coefficient 95% CI Regression coefficient 95% CI
Age (years) –0.0035 –0.0058––0.0013 –0.0055 –0.0074––0.0035
Weight (kg) 0.0022 0.0011–0.0032 0.0026 0.0017–0.0035
Blood Cd (nmol/L) –0.00044 –0.0012–0.00035 –0.0030 –0.0054––0.00066
Blood Pb (µmol/L) –0.048 –0.20–0.10 0.078 –0.057–0.21
Smoking (never or former/current) –0.020 –0.044–0.0035 0.019 –0.0077–0.045
aR2 = 0.21. bR2 = 0.28. 